Nevertheless, and in contrast to many of the earlier studies summarized above, these SMYD2 and SMYD3 inhibitors show no impact on the cell proliferation of more than 240 cancer cell lines regardless of genetic or histological background. The gene discussed is SMYD3; the disease is cancer.